Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 36

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 16
Chunk 36
---
12 months. As of December 31, 2024 and 2023, the unrealized losses, if any, on the Company’s short-term investments were primarily caused by interest rate increases. The Company does not expect the issuers to settle any security at a price less than the amortized cost basis of the investment with the contractual cash flows of these investments guaranteed by the issuer. No allowance for credit losses has been recorded since it is not more-likely-than-not that the Company will be required to sell the investments before recovery of their amortized cost basis. Realized gains and losses were immaterial for the year ended December 31, 2024. There were no realized gains and losses for the year ended December 31, 2023.

4. Balance Sheet ItemsPrepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following (in thousands):

        December 31,2024

        December 31,2023

        Prepaid research and development expenses
         
        $
        8,216

        $
        5,657

        Prepaid insurance

        830

        918

        Other prepaid expenses and other assets

        4,367

        2,352

        Total prepaid expenses and other current assets
         
        $
        13,413

        $
        8,927

        Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consisted of the following (in thousands):

        December 31,2024

        December 31,2023

        Accrued research and development expenses
         
        $
        18,760

        $
        12,643

        Accrued milestone payment

        20,000

        —

        Accrued payroll related expenses

        13,943

        9,165

        Accrued professional service expenses

        3,758

        3,675

        Other

        12,164

        1,041

        Total accrued expenses and other current liabilities
         
        $
        68,625

        $
        26,524

5. Intangible AssetsIntangible assets, net consisted of the following: 

        December 31,2024

        December 31,2023

        Intangible assets with finite lives:

        License agreement milestone payment
         
        $
        9,000

        $
        —

        PRV-related